文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于68Ga-HBED-CC PSMA-PET/CT的前列腺癌IMRT剂量绘画规划研究

Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference.
PubMed 文献 · Radiother Oncol · 2017-05-09

本研究对10例前列腺癌患者在前列腺切除术前行PSMA PET/CT,基于肿瘤内SUVmax 30%生成GTV-PET,比较全前列腺IMRT 77Gy(Plan77)与同步整合推量至95Gy(Plan95)的可行性及TCP/NTCP。结果显示两种计划均满足FLAME试验方案剂量约束,Plan95的TCP-histo和TCP-PET均显著高于Plan77,且直肠和膀胱NTCP无显著差异。

要点

  • PSMA PET/CT引导的IMRT剂量绘画技术可行,计划均满足剂量约束。
  • Plan95的TCP-histo平均96% vs Plan77的70%,差异显著(p<0.0001)。
  • Plan95的TCP-PET平均100% vs Plan77的55%,差异显著(p<0.0001)。

核心结论

  • 基于PSMA PET/CT的IMRT剂量绘画技术可行,可显著提高TCP而不增加直肠和膀胱NTCP。

研究设计与样本

  • 10例前列腺癌患者在前列腺切除术前接受PSMA PET/CT扫描,基于肿瘤内SUVmax 30%生成GTV-PET。
  • 每例患者生成两种IMRT计划:Plan77为全前列腺IMRT至77Gy,Plan95为全前列腺IMRT至77Gy并同步整合推量至GTV-PET 95Gy(35次)。
  • 计划可行性依据是否遵守FLAME试验方案判断,TCP-histo和TCP-PET分别基于配准的组织学GTV-histo和GTV-PET计算,并计算直肠和膀胱NTCP。

主要发现

  • 所有计划均达到处方剂量并遵守剂量约束。
  • Plan77和Plan95的GTV-histo平均剂量分别为75.8±0.3Gy和96.9±1Gy。
  • Plan77和Plan95的平均TCP-histo分别为70%(范围15-97%)和96%(范围78-100%,p<0.0001)。
  • Plan77和Plan95的平均TCP-PET分别为55%(范围27-82%)和100%(范围99-100%,p<0.0001)。
  • Plan95中TCP-PET与TCP-histo无显著差异(p=0.25),直肠和膀胱NTCP在两种计划间无显著差异(p=0.563和p=0.3)。

关键数值与推荐

  • GTV-PET基于肿瘤内SUVmax 30%生成。
  • Plan77:全前列腺IMRT至77Gy;Plan95:全前列腺IMRT至77Gy并同步整合推量至GTV-PET 95Gy,35次。
  • 计划可行性依据FLAME试验方案剂量约束判断。

临床怎么用

  • PSMA PET/CT引导的剂量绘画可在不增加直肠和膀胱NTCP的情况下提高TCP,支持进一步临床研究。

局限性

  • 研究为规划研究,样本量10例,尚未报告临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of IMRT dose painting using 68Ga-HBED-CC PSMA PET/CT for target delineation in prostate cancer (PCa). METHODS AND MATERIALS: 10 patients had PSMA PET/CT scans prior to prostatectomy. GTV-PET was generated on the basis of an intraprostatic SUVmax of 30%. Two IMRT plans were generated for each patient: Plan77 which consisted of whole-prostate IMRT to 77Gy, and Plan95 which consisted of whole-prostate IMRT to 77Gy and a simultaneous integrated boost to the GTV-PET up to 95Gy (35 fractions). The feasibility of these plans was judged by their ability to adhere to the FLAME trial protocol. TCP-histo/-PET were calculated on co-registered histology (GTV-histo) and GTV-PET, respectively. NTCPs for rectum and bladder were calculated. RESULTS: All plans reached prescription doses whilst adhering to dose constraints. In Plan77 and Plan95 mean doses in GTV-histo were 75.8±0.3Gy and 96.9±1Gy, respectively. Average TCP-histo values for Plan77 and Plan95 were 70% (range: 15-97%), and 96% (range: 78-100%, p<0.0001). Average TCP-PET values for Plan77 and Plan95 were 55% (range: 27-82%), and 100% (range: 99-100%, p<0.0001). There was no significant difference between TCP-PET and TCP-histo in Plan95 (p=0.25). There were no significant differences in rectal (p=0.563) and bladder (p=0.3) NTCPs. CONCLUSIONS: IMRT dose painting using PSMA PET/CT was technically feasible and resulted in significantly higher TCPs without higher NTCPs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zamboglou C, Sachpazidis I, Koubar K, et al. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiother Oncol. 2017. PMID: 28499607. doi:10.1016/j.radonc.2017.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。